A French medical know-how startup targeted on “remodeling prenatal medication” lately gained $14 million in Sequence A funding.
The Paris-based firm, named Sonio, has now raised $20 million because it was based in 2020. Its Sequence A financing spherical was led by Cross Border Influence Ventures and Elaia.
Sonio’s AI platform automates ultrasound reporting. The know-how is supposed to allow healthcare suppliers to conduct ultrasound exams with better accuracy, pace and effectivity, CEO Cécile Brosset advised MedCity Information.
“We’re targeted on streamlining the end-to-end workflow for practitioners — from sharing the ultrasound pictures with the sufferers to reporting, and from high quality assurance to anomaly detection. We wish to cowl each small process and optimize the medical time being utilized. Our intention is to cut back healthcare specialists’ time to do low-value-added duties, to allow them to deal with different essential features,” she declared.
The corporate receives pictures as they’re acquired by the sonographer, whatever the ultrasound machine’s mannequin or model, Brosset defined. Sonio’s AI platform then processes these pictures within the cloud and supplies practitioners with a real-time evaluation. The startup claims that its know-how can determine greater than 300 potential prenatal syndromes and anomalies with an accuracy charge of no less than 95%.
Sonio’s platform additionally features a scientific resolution assist instrument designed to prioritize potential uncommon diagnoses.
“It’s educated on knowledgeable literature explaining which indicators are most likely related to completely different pathologies. This kind of AI doesn’t study from pictures, however from proprietary text-based scientific databases. It principally mimics scientific reasoning by means of a really complicated statistical resolution tree,” Brosset stated.
The corporate sells its software program to hospitals, ladies’s well being teams and personal doctor practices. These suppliers should buy both a month-to-month or yearly subscription.
Brosset recognized GE HealthCare, Ultrasound.ai, Diagnoly and AS Software program as a few of Sonio’s greatest opponents. When requested how her startup units itself other than these firms, she stated that Sonio’s purpose “isn’t just to develop superior tech, however to save lots of lives with the assistance of the tech” — but it surely’s most likely secure to imagine that Sonio’s opponents are eager on saving lives as effectively.
With its new fundraise, Sonio plans to develop its crew and provoke its industrial improvement within the U.S.
The corporate’s know-how has been cleared to be used in Europe, but it surely hasn’t been cleared by the FDA but. Brosset declined to reply MedCity’s query about whether or not there’s a reimbursement path for Sonio’s know-how.
Picture: Blue Planet Studio, Getty Photos